By Tony Fong

NEW YORK (GenomeWeb News) – The number of mergers and acquisitions in the genomics tools and molecular diagnostics markets in 2011 was flat compared to 2010 as a strong start to the year fizzled out in the second half.

Despite the late-year lull, some experts are predicting a rebound in M&A activity over the next couple of years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.